Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The study will assess the efficacy and safety of oral MT-1303 compared to placebo at 12 weeks
as the induction treatment in subjects with active mild to moderate ulcerative colitis (UC),
as well as maintenance treatment with open-label MT-1303 for up to 36 weeks.